🇺🇸 FDA
Patent

US 6630464

Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer

expired A61KA61K31/433A61K31/549

Quick answer

US patent 6630464 (Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Oct 07 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/433, A61K31/549, A61P, A61P35/00